DexCom, Inc. (DXCM) vs West Pharmaceutical Services, Inc. (WST)
DXCM leads on 14 of 16 compared metrics.
A side-by-side comparison of DexCom, Inc. and West Pharmaceutical Services, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 26, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
DXCM
DexCom, Inc.
$68.65Healthcare
WST
West Pharmaceutical Services, Inc.
$350.85Healthcare
Total return — DXCM vs WST
growth of $100 · last 21yDXCM +2258.2%WST +2802.0%WST compounded faster
DXCM WST
DXCM vs WST: by the numbers
- •DXCM is the larger company ($26.76B vs $24.79B market cap).
- •DXCM trades at the lower earnings multiple (29.34 vs 46.84 P/E).
- •DXCM converts more revenue to profit (19.31% vs 16.85% net margin).
- •DXCM grew revenue faster over the past five years (18.91% vs 6.72% CAGR).
- •WST pays a dividend (0.25% yield) while DXCM does not currently pay one.
Which is better, DXCM or WST?
Metric tally: DXCM 14 · WST 2It depends on what you're optimizing for:
ValueDXCM(lower P/E)
GrowthDXCM(faster 5Y revenue CAGR)
QualityDXCM(higher ROIC)
Metrics side by side
Valuation
| Metric | DXCM | WST |
|---|---|---|
| P/E ratio | 29.34● | 46.84 |
| Forward P/E | 22.23● | 36.63 |
| P/S ratio | 5.61● | 7.89 |
| P/B ratio | 9.14 | 8.49● |
| PEG ratio | 0.67● | 33.99 |
| EV / EBITDA | 21.12● | 29.94 |
| FCF yield | 5.29%● | 1.80% |
Profitability
| Metric | DXCM | WST |
|---|---|---|
| Gross margin | 61.84%● | 36.24% |
| Operating margin | 21.45%● | 20.67% |
| Net margin | 19.31%● | 16.85% |
| ROE | 31.47%● | 18.15% |
| ROIC | 16.61%● | 13.62% |
Dividends
| Metric | DXCM | WST |
|---|---|---|
| Dividend yield | — | 0.25% |
| Payout ratio | — | 12.88% |
Growth (annualized)
| Metric | DXCM | WST |
|---|---|---|
| Revenue CAGR (5Y) | 18.91%● | 6.72% |
| EPS CAGR (5Y) | 10.31%● | 7.85% |
| FCF CAGR (5Y) | 43.37%● | 8.32% |
| Total return CAGR (5Y) | -8.41% | -0.26%● |
Frequently asked
- Which is better, DXCM or WST?
- It depends on your goal. value: DXCM (lower P/E); growth: DXCM (faster 5Y revenue CAGR); quality: DXCM (higher ROIC). Across all compared metrics, DXCM leads 14 to 2.
- Is DXCM or WST cheaper?
- On trailing earnings, DXCM is cheaper: DXCM trades at a 29.34 P/E and WST at 46.84.
- Which has grown faster, DXCM or WST?
- Over the past five years, DXCM grew revenue faster — DXCM at a 18.91% CAGR versus WST at 6.72%.
- Does DXCM or WST pay a bigger dividend?
- WST pays a dividend (0.25% yield) while DXCM does not currently pay one.
- Is DXCM or WST more profitable?
- DXCM runs the higher net margin — DXCM at 19.31% versus WST at 16.85%.
- Which has been the better investment, DXCM or WST?
- Over the past 10-year, WST delivered the higher annualized total return — DXCM at 13.60% versus WST at 17.45%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
DexCom P/E ratioWest Pharmaceutical Services P/E ratioDexCom dividend yieldWest Pharmaceutical Services dividend yieldDexCom ROEWest Pharmaceutical Services ROEDexCom operating marginWest Pharmaceutical Services operating marginDexCom revenue growthWest Pharmaceutical Services revenue growthDexCom free cash flowWest Pharmaceutical Services free cash flow
DexCom & West Pharmaceutical Services appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 26, 2026.